Milestone Scientific (MLSS)
Market Price (9/21/2026): $0.444 | Market Cap: $41.3 MilSector: Health Care | Industry: Health Care Equipment
Milestone Scientific (MLSS)
Market Price (9/21/2026): $0.444Market Cap: $41.3 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Precision Medicine, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -93%, 3Y Excs Rtn is -132% | Penny stockMkt Price is 0.4 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -44% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.3% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 17% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.8%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.0% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% Key risksMLSS key risks include [1] financial instability, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -93%, 3Y Excs Rtn is -132% |
| Penny stockMkt Price is 0.4 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -44% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.3% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.8%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.0% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15% |
| Key risksMLSS key risks include [1] financial instability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Milestone Scientific (MLSS) stock has gained about 5% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Second Quarter 2026 Financial Performance, driven by significant growth in the Medical Segment.
Milestone Scientific reported its fiscal Q2 2026 earnings on August 12, 2026, with total revenue increasing 22% year-over-year to $2.8 million, surpassing analyst expectations of $2.70 million. This strong top-line growth was primarily fueled by its medical business, with CompuFlo® revenue surging 231% compared to the fiscal second quarter of last year, indicating growing physician adoption and market penetration for its specialized medical devices. The company also managed to narrow its net loss to $1.1 million from $1.5 million in the prior-year quarter, partly due to a 4.2% year-over-year decrease in operating expenses to approximately $3.0 million.
2. Enhanced Commercialization and Reimbursement Progress for the CompuFlo® Epidural System.
Milestone Scientific made significant strides in expanding the market access and reimbursement for its CompuFlo® Epidural System during this period. The company announced a strategic distribution agreement to broaden CompuFlo® access across VA and Department of Defense Health Systems, further solidifying its presence in the federal healthcare sector. Additionally, Milestone Scientific achieved progress in Medicare reimbursement, with approximately $325 per procedure now covered under CPT® 0777T through Novitas and First Coast, extending coverage across three regions and 13 states. This reimbursement progress and expanded distribution network are crucial for accelerating the commercial adoption of its medical products.
Show more
Milestone Scientific (MLSS) stock has gained about 5% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Second Quarter 2026 Financial Performance, driven by significant growth in the Medical Segment.
Milestone Scientific reported its fiscal Q2 2026 earnings on August 12, 2026, with total revenue increasing 22% year-over-year to $2.8 million, surpassing analyst expectations of $2.70 million. This strong top-line growth was primarily fueled by its medical business, with CompuFlo® revenue surging 231% compared to the fiscal second quarter of last year, indicating growing physician adoption and market penetration for its specialized medical devices. The company also managed to narrow its net loss to $1.1 million from $1.5 million in the prior-year quarter, partly due to a 4.2% year-over-year decrease in operating expenses to approximately $3.0 million.
2. Enhanced Commercialization and Reimbursement Progress for the CompuFlo® Epidural System.
Milestone Scientific made significant strides in expanding the market access and reimbursement for its CompuFlo® Epidural System during this period. The company announced a strategic distribution agreement to broaden CompuFlo® access across VA and Department of Defense Health Systems, further solidifying its presence in the federal healthcare sector. Additionally, Milestone Scientific achieved progress in Medicare reimbursement, with approximately $325 per procedure now covered under CPT® 0777T through Novitas and First Coast, extending coverage across three regions and 13 states. This reimbursement progress and expanded distribution network are crucial for accelerating the commercial adoption of its medical products.
3. Improved Financial Stability with a Debt-Free Balance Sheet.
The company significantly strengthened its financial position by achieving a debt-free balance sheet on August 26, 2026. This was accomplished when three members of its Board of Directors converted $465,000 of outstanding loans owed by the Company into common stock. This debt-to-equity conversion, executed at a rate of $0.50 per share, eliminated the company's outstanding note payable, reducing financial risk and demonstrating leadership's confidence in Milestone Scientific's future prospects.
4. Positive Analyst Sentiment and Price Target Upside.
Analyst ratings reflected a favorable outlook for Milestone Scientific, with a consensus rating of "Buy" or "Strong Buy" from multiple analysts. Analysts have established a median 12-month price target for MLSS ranging from $1.00 to $1.25. One analyst's median 12-month price target of $1.25 represents a substantial potential upside of 149% from a recent closing price. This positive analyst sentiment, coupled with the company's operational achievements, contributed to investor confidence and the stock's upward trend.
Show less
Stock Movement Drivers
Fundamental Drivers
The 5.3% change in MLSS stock from 5/31/2026 to 9/20/2026 was primarily driven by a 9.0% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.39 | 0.41 | 5.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 9 | 5.8% |
| P/S Multiple | 3.7 | 4.0 | 9.0% |
| Shares Outstanding (Mil) | 85 | 93 | -8.7% |
| Cumulative Contribution | 5.3% |
Market Drivers
5/31/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| MLSS | 5.3% | |
| Market (SPY) | 0.9% | 34.9% |
| Sector (XLV) | 12.7% | -0.4% |
Fundamental Drivers
The 54.0% change in MLSS stock from 2/28/2026 to 9/20/2026 was primarily driven by a 65.1% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.26 | 0.41 | 54.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 9 | 5.5% |
| P/S Multiple | 2.4 | 4.0 | 65.1% |
| Shares Outstanding (Mil) | 82 | 93 | -11.6% |
| Cumulative Contribution | 54.0% |
Market Drivers
2/28/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| MLSS | 54.0% | |
| Market (SPY) | 11.6% | 22.8% |
| Sector (XLV) | 5.5% | -0.3% |
Fundamental Drivers
The -30.9% change in MLSS stock from 8/31/2025 to 9/20/2026 was primarily driven by a -24.4% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.59 | 0.41 | -30.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 9 | 3.7% |
| P/S Multiple | 5.3 | 4.0 | -24.4% |
| Shares Outstanding (Mil) | 82 | 93 | -11.9% |
| Cumulative Contribution | -30.9% |
Market Drivers
8/31/2025 to 9/20/2026| Return | Correlation | |
|---|---|---|
| MLSS | -30.9% | |
| Market (SPY) | 19.4% | 19.3% |
| Sector (XLV) | 24.1% | -2.8% |
Fundamental Drivers
The -61.9% change in MLSS stock from 8/31/2023 to 9/20/2026 was primarily driven by a -48.1% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.07 | 0.41 | -61.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 9 | -5.4% |
| P/S Multiple | 7.8 | 4.0 | -48.1% |
| Shares Outstanding (Mil) | 72 | 93 | -22.3% |
| Cumulative Contribution | -61.9% |
Market Drivers
8/31/2023 to 9/20/2026| Return | Correlation | |
|---|---|---|
| MLSS | -61.9% | |
| Market (SPY) | 75.6% | 19.6% |
| Sector (XLV) | 32.3% | 6.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MLSS Return | -3% | -77% | 44% | 39% | -72% | 55% | -80% |
| Peers Return | 13% | -24% | -14% | -4% | -11% | 5% | -33% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| MLSS Win Rate | 50% | 33% | 42% | 42% | 25% | 67% | |
| Peers Win Rate | 46% | 42% | 48% | 42% | 42% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| MLSS Max Drawdown | -67% | -81% | -57% | -44% | -79% | -36% | |
| Peers Max Drawdown | -18% | -39% | -41% | -30% | -38% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: XRAY, NVST, BDX, ICUI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
| Event | MLSS | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -43.9% | -9.5% |
| % Gain to Breakeven | 78.3% | 10.5% |
| Time to Breakeven | 223 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -62.7% | -33.7% |
| % Gain to Breakeven | 167.7% | 50.9% |
| Time to Breakeven | 61 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -62.0% | -19.2% |
| % Gain to Breakeven | 163.4% | 23.8% |
| Time to Breakeven | 248 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -41.5% | -3.7% |
| % Gain to Breakeven | 70.8% | 3.9% |
| Time to Breakeven | 1117 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -55.4% | -12.2% |
| % Gain to Breakeven | 124.4% | 13.9% |
| Time to Breakeven | 118 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -37.1% | -6.8% |
| % Gain to Breakeven | 59.1% | 7.3% |
| Time to Breakeven | 82 days | 15 days |
In The Past
Milestone Scientific's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MLSS | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -43.9% | -9.5% |
| % Gain to Breakeven | 78.3% | 10.5% |
| Time to Breakeven | 223 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -62.7% | -33.7% |
| % Gain to Breakeven | 167.7% | 50.9% |
| Time to Breakeven | 61 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -62.0% | -19.2% |
| % Gain to Breakeven | 163.4% | 23.8% |
| Time to Breakeven | 248 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -41.5% | -3.7% |
| % Gain to Breakeven | 70.8% | 3.9% |
| Time to Breakeven | 1117 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -55.4% | -12.2% |
| % Gain to Breakeven | 124.4% | 13.9% |
| Time to Breakeven | 118 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -37.1% | -6.8% |
| % Gain to Breakeven | 59.1% | 7.3% |
| Time to Breakeven | 82 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -50.8% | -17.9% |
| % Gain to Breakeven | 103.3% | 21.8% |
| Time to Breakeven | 14 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -25.0% | -15.4% |
| % Gain to Breakeven | 33.3% | 18.2% |
| Time to Breakeven | 899 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -87.1% | -53.4% |
| % Gain to Breakeven | 675.0% | 114.4% |
| Time to Breakeven | 376 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -28.3% | -8.6% |
| % Gain to Breakeven | 39.4% | 9.5% |
| Time to Breakeven | 43 days | 47 days |
In The Past
Milestone Scientific's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Milestone Scientific (MLSS)
Milestone Scientific (MLSS) is a medical technology company that designs, develops, and commercializes advanced diagnostic and therapeutic injection technologies and devices. These innovative systems are engineered for precise and controlled delivery of substances, as well as for the aspiration of fluids, catering to a wide range of applications in the medical, dental, and cosmetic sectors. The company operates globally, serving markets in the United States, China, and other international regions.
The company's product portfolio is categorized into Dental and Medical segments. Its dental offerings, such as CompuDent and the STA Single Tooth Anesthesia System, are crucial for local anesthetic delivery across all dental procedures. In the medical segment, Milestone Scientific provides CompuFlo, a computer-controlled drug delivery system for the painless administration of drugs and anesthetics, along with a disposable injection handpiece. Specialized systems include CompuFlo Epidural for various medical anesthesia applications and CompuMed, which is utilized in diverse fields including plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, and orthopedics. These products primarily serve healthcare professionals, including dentists, surgeons, and specialists in numerous medical disciplines who require sophisticated solutions for injection and aspiration.
AI Analysis | Feedback
Here are a few brief analogies for Milestone Scientific (MLSS):
It's like Dyson for medical injection devices, engineering advanced, computer-controlled systems for precision and patient comfort.
Think of it as Becton Dickinson (BD) if they specialized in smart, computer-controlled injection and drug delivery systems designed for accuracy and reduced pain.
AI Analysis | Feedback
- CompuDent: A system used for dental procedures requiring local anesthetic.
- STA Single Tooth Anesthesia System: A system used for all dental procedures that require local anesthetic.
- CompuFlo: A computer-controlled drug delivery system for painless delivery of drugs and aspiration of bodily fluids.
- Disposable injection handpiece: An accessory providing tactile control during injections.
- CompuFlo Epidural: A computer-controlled anesthesia system specifically designed for various medical applications requiring epidural anesthesia.
- CompuMed: A device used in various medical procedures including plastic surgery, hair restoration, podiatry, and dermatology.
AI Analysis | Feedback
Milestone Scientific (MLSS) primarily sells its diagnostic and therapeutic injection technologies and devices to other companies, specifically professional entities within the medical and dental fields, rather than directly to individuals. The company's SEC filings indicate that no single customer accounted for 10% or more of its net revenues, meaning there are no major named corporate customers (such as publicly traded companies) that individually represent a significant portion of its sales.
Therefore, Milestone Scientific serves a broad base of professional customers, which can be categorized as follows:
- Dental Practices and Clinics: These customers utilize Milestone Scientific's dental products such as the CompuDent and STA Single Tooth Anesthesia System for various dental procedures requiring local anesthetic.
- Hospitals, Medical Centers, and Pain Management Centers: These institutions are customers for Milestone Scientific's medical systems, including CompuFlo Epidural for anesthesia and other CompuFlo systems for the computer-controlled delivery of drugs and anesthetics in a variety of medical applications.
- Specialty Medical Clinics and Physicians' Offices: This category encompasses various specialized medical practices such as those in plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, and orthopedics. These customers use systems like CompuMed and CompuFlo for specific medical procedures and drug delivery.
AI Analysis | Feedback
NPI Medical
PMP Corporation
AI Analysis | Feedback
Eric C. Hines, Chief Executive Officer
Eric C. Hines was appointed Chief Executive Officer of Milestone Scientific, effective August 1, 2025. He brings over 25 years of leadership experience, specializing in scaling sales-driven enterprise software companies. Prior to joining Milestone Scientific, he served as President of North America at Ex Libris, a division of Clarivate, where he successfully doubled the annual revenue from approximately $50 million to over $100 million. At Ex Libris, he was responsible for operations across the U.S., Canada, and Latin America, and played a key role in launching multiple new product lines and managing sales, marketing, and service organizations. Earlier in his career, Mr. Hines held executive positions at NICE Systems, where he led a significant North American security business and oversaw the Customer Experience Management (CEM) division.
Peter Milligan, Chief Financial Officer
Peter Milligan was appointed as Milestone Scientific's Chief Financial Officer on a part-time basis, effective February 1, 2023. Mr. Milligan has extensive experience in finance leadership within various companies. From 2018 to March 2021, he served as Chief Financial Officer of Melinta Therapeutics, LLC, where he guided the company through its Chapter 11 reorganization. Before that, he was the Chief Financial Officer at G&W Laboratories Inc. from 2016 to 2018. Notably, Mr. Milligan was the Senior Vice President and Chief Financial Officer of Exelis Inc., following its spin-off from ITT Inc. in 2011, and continued in this role through the sale of the business to Harris Corp. in 2015. He also served as a fractional Chief Financial Officer for early-stage bio-technology companies, including Travecta Therapeutics Pte. Ltd. (August 2021 to October 2022) and Vinci Pharmaceuticals Inc. (June 2021 to October 2022). His background also includes over a decade at AT&T in various finance roles and prior senior finance positions within ITT Inc.
AI Analysis | Feedback
The key risks to Milestone Scientific's business operations and financial health include significant financial instability, intense competition in the medical and dental device markets, and ongoing regulatory hurdles.
1. Financial Instability and Going Concern Risk
Milestone Scientific faces substantial financial challenges, including a history of consistent net losses over its five most recent fiscal years. The company's stockholders' equity of approximately $3.3 million is significantly below the NYSE American's continued listing standards, which require $4 million or $6 million depending on the number of loss-making years, leading to a notice of non-compliance and potential delisting. Furthermore, the company's Altman Z-Score of -18.64 indicates a potential risk of bankruptcy within the next two years. Milestone Scientific operates with negative cash flow and relies on external financing to sustain its operations, and it has less than one year of cash runway with no forecast of profitability over the next three years.
2. Intense Competition and Commercialization Challenges
Operating in the highly competitive medical and dental device landscape, Milestone Scientific, as a micro-cap company, struggles against larger competitors such as Dentsply Sirona and Straumann Group AG. These larger entities possess superior sales and marketing infrastructure, established distribution channels, and brand recognition, allowing them to outspend MLSS, bundle products, and leverage long-standing relationships with practitioners. The company faces significant challenges in translating its proprietary Dynamic Pressure Sensing® (DPS) technology into widespread commercial success and achieving financial stability. The effectiveness of its direct sales model relies heavily on successful marketing, customer acquisition, and retention. Additionally, healthcare cost pressures and premium pricing for its products could hinder market adoption and restrict future revenue, particularly as hospitals limit capital expenditures.
3. Regulatory Hurdles and Product Approval Risks
As a medical device company, Milestone Scientific is subject to rigorous regulatory challenges. There is a risk that the U.S. Food and Drug Administration (FDA) could disagree with the company's assessments regarding the necessity of new 510(k) clearances for product modifications. Such a disagreement could force Milestone Scientific to cease marketing or recall modified products until new clearances are obtained, potentially leading to significant regulatory fines or penalties. Furthermore, any changes in federal and state regulatory agencies could introduce disruptions and delays in the product approval processes.
AI Analysis | Feedback
AI Analysis | Feedback
Milestone Scientific Inc. (MLSS) designs, develops, and commercializes diagnostic and therapeutic injection technologies and devices for medical, dental, and cosmetic use. The addressable markets for its main products and services are substantial across various regions.
Dental Segment (CompuDent and STA Single Tooth Anesthesia System)
- The global dental anesthetics market was valued at approximately USD 2.42 billion in 2025 and is projected to increase to about USD 3.94 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of 4.99% from 2026 to 2035.
- Another estimate places the global dental anesthetics market at USD 1.73 billion in 2025, with a projected growth to USD 2.33 billion by 2031 at a CAGR of 5.07%.
- Computer-controlled local anesthetic delivery systems are a growing sub-segment, expected to expand at a 7.78% CAGR through 2031.
- North America represented the largest share of the dental anesthetics market, holding 41.72% of the revenue in 2025. The Asia-Pacific region is also a significant market, with an estimated size of USD 943.80 million in 2025 and a projection to reach around USD 1,574.20 million by 2035, at a CAGR of 5.25%.
Medical Segment (CompuFlo, CompuFlo Epidural, and CompuMed)
CompuFlo (Computer-controlled drug delivery systems)
- The global electronic drug delivery systems market was valued at USD 13.80 billion in 2025 and is projected to reach USD 30.22 billion by 2034, demonstrating a CAGR of 9.1%.
- The global smart drug delivery systems market was estimated at USD 10.5 billion in 2023 and is anticipated to grow to USD 48.3 billion by 2034, with a CAGR of 17% from 2025.
- The global controlled release drug delivery market, another related market, was estimated at USD 59.8 billion in 2024 and is projected to reach USD 148.6 billion by 2033, growing at a CAGR of 10.7%.
- North America held approximately 44.7% of the electronic drug delivery systems market in 2024.
CompuFlo Epidural (Epidural anesthesia systems)
- Approximately 11 million epidural procedures are performed annually in the U.S.
- The global epidural anesthesia disposable device market is expected to grow from USD 1.76 billion in 2025 to USD 2.79 billion in 2030, at a CAGR of 9.7%.
- The global epidural anesthesia system market is projected to grow from USD 3.22 billion in 2025 to USD 5.31 billion by 2032, at a CAGR of 7.40%.
- The global epidural and spinal anesthesia drug market was valued at USD 1.25 billion in 2025 and is expected to reach USD 1.76 billion by 2034, with a CAGR of 5.1%.
- North America was the largest regional market for epidural anesthesia disposable devices in 2025. Specifically, the addressable market for the CompuFlo Epidural System among Florida Medicare patients alone is an estimated USD 125 million.
CompuMed (Devices for various medical procedures)
- Dermatology: The global dermatology devices market size was estimated at USD 13.9 billion in 2023 and is projected to reach USD 34.34 billion by 2030, growing at a CAGR of 12.6%. North America held the largest revenue share of 43.00% in 2023.
- Hair Restoration: The global hair restoration market size was estimated at USD 6,463.0 million in 2023 and is projected to reach USD 18,923.4 million by 2030, growing at a CAGR of 16.6%. North America held a 40.05% share of the hair restoration services market in 2025.
- Colorectal Surgery: The global colorectal surgery market is valued at USD 15.4 billion in 2024 and is projected to reach USD 23.1 billion by 2030, with a CAGR of 6.9%. North America accounted for the largest market share at 39% in 2024. The global colorectal surgical devices market is expected to be worth USD 27,559.70 million by 2029.
- Podiatry: The global podiatry devices market is estimated to be worth approximately USD 6.5 billion in 2024 and is projected to reach around USD 9 billion by 2029, exhibiting a CAGR of approximately 6%. North America is the largest market for podiatry equipment, holding approximately 45% of the global market share.
- Orthopedics: The global orthopedic devices market size is calculated at USD 65.79 billion in 2025 and is predicted to increase to approximately USD 100.33 billion by 2035, expanding at a CAGR of 4.31%. North America dominated the global market with the largest market share of 46% in 2025.
AI Analysis | Feedback
Milestone Scientific (MLSS) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
-
Expansion of the Dental Segment: The company is focused on expanding its dental sales, both internationally and within North America. This includes pursuing new international registrations for the STA Single Tooth Anesthesia System and strengthening direct sales and omnichannel marketing efforts for the STA system in North America.
-
Commercialization and Reimbursement of the CompuFlo Epidural System: Milestone Scientific is actively working on the commercial rollout of its CompuFlo Epidural System for medical applications. Significant progress has been made in securing Medicare Part B payment coverage and gaining support from commercial insurers. The company is executing a guided relaunch and reimbursement strategy in medical markets, reinforced by the launch of the CompuFlo Advisor Program aimed at accelerating commercial adoption and improving Medicare reimbursement.
-
Growth in Recurring Revenue from CompuFlo Disposables: As the CompuFlo Epidural System gains adoption, there is an expected increase in recurring revenue from the sales of its associated disposable handpieces. The CompuFlo Advisor Program specifically targets increasing this recurring disposable revenue.
-
Enhanced Sales and Marketing Strategies Under New Leadership: With recent changes in leadership, including the appointment of a new CEO, Milestone Scientific is implementing a more focused approach with targeted customer groups and an emphasis on improving sales execution and leadership. This strategic refinement is anticipated to drive overall commercial success.
AI Analysis | Feedback
Share Repurchases
- Milestone Scientific has shown a negative 3-Year Share Buyback Ratio of -4.60% as of September 2025, and consistently negative ratios historically, indicating that the company has been issuing shares rather than repurchasing them over the past three to five years.
Share Issuance
- Milestone Scientific increased its authorized common stock from 100,000,000 to 125,000,000 shares, effective March 10, 2026, after receiving stockholder approval on December 18, 2025. This amendment provides the company with flexibility for future equity financings, stock-based compensation, or strategic transactions.
- The company's outstanding shares have increased from 69.57 million in 2021 to 82.32 million in 2025 and as of February 2026, reflecting consistent share issuances over this period.
- Annual increases in outstanding shares include 5.71% in 2021, 2.01% in 2022, 3.88% in 2023, 8.46% in 2024, and 2.95% in 2025.
Inbound Investments
- On April 8, 2024, Milestone Scientific received $1,983,095 from Comcast Corporation through the sale of its unused Net Operating Losses (NOLs) and Research & Development (R&D) tax credits. These funds are designated for general corporate purposes and working capital.
Capital Expenditures
- Milestone Scientific reported capital expenditures of $120,000 for the nine months ended September 30, 2025, and $112,000 for the nine months ended September 30, 2024.
- For the full year 2024, capital expenditures were $119,000, while in 2023, they amounted to $178,000.
- In 2022, the company's capital expenditures were $80,000, and in 2021, they were $118,000.
Peer Outperformance in Health Care Equipment
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| MLSS | Milestone Scientific | -1.3% | -9.2x | -21.4% | -58.2% | -77.1% | — |
| RVTY | Revvity | 0.9% | 67.4x | 65.9% | 33.3% | -21.4% | +56pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 16.2% | 43.2% | 90.1% | CAH 392% · MCK 346% · COR 168% |
| Managed Health Care | 8 | 40.4% | -5.3% | 2.3% | OSCR 84% · HQY 56% · ELV 17% |
| Health Care Services | 20 | 21.1% | 37.6% | -0.3% | HIMS 239% · RDNT 173% · DGX 76% |
| Health Care Facilities | 24 | 6.0% | 6.5% | -4.5% | NHC 271% · THC 261% · ENSG 129% |
| Health Care Equipment ← | 50 | -2.7% | -0.2% | -21.1% | POCI 11050% · UFPT 341% · GKOS 222% |
| Pharmaceuticals | 62 | -10.5% | 14.8% | -38.6% | LQDA 2472% · INDV 1099% · ETON 1051% |
| Health Care Supplies | 12 | 14.1% | -8.9% | -39.7% | LNTH 287% · HAE 54% · MMSI 20% |
| Life Sciences Tools & Services | 109 | 4.3% | -11.3% | -68.4% | SNWV 1757% · MEDP 231% · NTRA 199% |
| Health Care Technology | 21 | -25.8% | -52.6% | -79.2% | SPOK 68% · HSTM 3% · VEEV -13% |
| Biotechnology | 364 | 0.6% | -21.7% | -79.4% | CELZ 1280% · DNTH 1221% · ELVN 1069% |
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 23.35 |
| Mkt Cap | 3.8 |
| Rev LTM | 2,856 |
| Op Inc LTM | 184 |
| FCF LTM | 145 |
| FCF 3Y Avg | 215 |
| CFO LTM | 303 |
| CFO 3Y Avg | 309 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.7% |
| Rev Chg 3Y Avg | -1.3% |
| Rev Chg Q | 5.4% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Inc Chg LTM | 26.1% |
| Op Inc Chg 3Y Avg | 10.7% |
| Op Mgn LTM | 6.7% |
| Op Mgn 3Y Avg | 6.3% |
| QoQ Delta Op Mgn LTM | 1.0% |
| CFO/Rev LTM | 10.6% |
| CFO/Rev 3Y Avg | 10.0% |
| FCF/Rev LTM | 6.7% |
| FCF/Rev 3Y Avg | 5.7% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Dental | 9 | 9 | 10 | 9 | 10 |
| Medical | 0 | 0 | 0 | 0 | 0 |
| Corporate | 0 | 0 | 0 | ||
| Total | 9 | 9 | 10 | 9 | 10 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Dental | 2 | 2 | 2 | 1 | 2 |
| Medical | -1 | -2 | -4 | -5 | -4 |
| Corporate | -6 | -6 | -5 | -5 | -6 |
| Total | -6 | -7 | -7 | -9 | -7 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Dental | 6 | 5 | 5 | 4 | 6 |
| Corporate | 2 | 4 | 6 | 9 | 12 |
| Medical | 0 | 0 | 0 | 1 | 1 |
| Total | 8 | 10 | 11 | 14 | 20 |
Price Behavior
| Market Price | $0.41 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/03/1995 | |
| Distance from 52W High | -26.3% | |
| 50 Days | 200 Days | |
| DMA Price | $0.45 | $0.35 |
| DMA Trend | up | up |
| Distance from DMA | -9.0% | 16.1% |
| 3M | 1YR | |
| Volatility | 77.4% | 83.5% |
| Downside Capture | 414.66 | 197.66 |
| Upside Capture | 427.90 | 136.07 |
| Correlation (SPY) | 50.5% | 19.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.11 | 3.30 | 1.88 | 1.35 | 1.14 | 1.02 |
| Up Beta | 1.07 | 0.70 | -1.36 | -0.52 | -0.30 | 0.63 |
| Down Beta | -3.66 | 3.23 | 2.43 | 3.22 | 1.77 | 1.53 |
| Up Capture | 607% | 669% | 411% | 253% | 120% | 42% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 12 | 25 | 36 | 69 | 116 | 336 |
| Down Capture | 399% | 304% | 208% | 97% | 141% | 106% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 9 | 17 | 27 | 56 | 132 | 398 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MLSS | |
|---|---|---|---|---|
| MLSS | -26.1% | 83.2% | -0.00 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | -3.5% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 19.6% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | 1.3% |
| Commodities (DBC) | 46.3% | 20.6% | 1.73 | -16.0% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | 3.7% |
| Bitcoin (BTCUSD) | -30.6% | 44.3% | -0.70 | 15.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MLSS | |
|---|---|---|---|---|
| MLSS | -28.4% | 84.6% | -0.02 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | 11.4% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 23.0% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 4.9% |
| Commodities (DBC) | 11.2% | 19.5% | 0.45 | 2.9% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 15.5% |
| Bitcoin (BTCUSD) | 12.5% | 52.5% | 0.42 | 13.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MLSS | |
|---|---|---|---|---|
| MLSS | -16.2% | 87.7% | 0.20 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 10.4% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 18.5% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 3.9% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | 4.5% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | 13.9% |
| Bitcoin (BTCUSD) | 62.6% | 66.2% | 1.02 | 7.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/13/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/13/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/13/2021 | 10-Q |
| 03/31/2021 | 05/14/2021 | 10-Q |
| 12/31/2020 | 03/31/2021 | 10-K |
| 09/30/2020 | 11/16/2020 | 10-Q |
| 06/30/2020 | 08/14/2020 | 10-Q |
| 03/31/2020 | 05/15/2020 | 10-Q |
| 12/31/2019 | 03/30/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bp4, S.r.l. | Direct | Sell | 10292025 | 0.44 | 100,000 | 43,980 | 3,912,797 | Form | |
| 2 | Bp4, S.r.l. | Direct | Sell | 10292025 | 0.43 | 80,000 | 34,416 | 3,870,408 | Form | |
| 3 | Bp4, S.r.l. | Direct | Sell | 10292025 | 0.45 | 14,427 | 6,488 | 4,081,821 | Form | |
| 4 | Bp4, S.r.l. | Direct | Sell | 10232025 | 0.44 | 40,000 | 17,592 | 3,998,306 | Form | |
| 5 | Bp4, S.r.l. | Direct | Sell | 10232025 | 0.45 | 24,034 | 10,880 | 4,133,691 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bp4, S.r.l. | Direct | Sell | 10292025 | 0.44 | 100,000 | 43,980 | 3,912,797 | Form | |
| 2 | Bp4, S.r.l. | Direct | Sell | 10292025 | 0.43 | 80,000 | 34,416 | 3,870,408 | Form | |
| 3 | Bp4, S.r.l. | Direct | Sell | 10292025 | 0.45 | 14,427 | 6,488 | 4,081,821 | Form | |
| 4 | Bp4, S.r.l. | Direct | Sell | 10232025 | 0.44 | 40,000 | 17,592 | 3,998,306 | Form | |
| 5 | Bp4, S.r.l. | Direct | Sell | 10232025 | 0.45 | 24,034 | 10,880 | 4,133,691 | Form | |
| 6 | Bp4, S.r.l. | Direct | Sell | 10172025 | 0.54 | 30,000 | 16,185 | 4,939,244 | Form | |
| 7 | Bp4, S.r.l. | Direct | Sell | 10172025 | 0.55 | 10,000 | 5,500 | 5,046,374 | Form | |
| 8 | Bp4, S.r.l. | Direct | Sell | 10172025 | 0.55 | 10,158 | 5,588 | 5,052,793 | Form | |
| 9 | Bp4, S.r.l. | Direct | Sell | 10092025 | 0.47 | 30,000 | 13,950 | 4,275,854 | Form | |
| 10 | Bp4, S.r.l. | Direct | Sell | 10092025 | 0.45 | 10,000 | 4,500 | 4,151,423 | Form | |
| 11 | Bp4, S.r.l. | Direct | Sell | 10082025 | 0.45 | 19,210 | 8,636 | 4,151,938 | Form | |
| 12 | Bp4, S.r.l. | Direct | Sell | 9152025 | 0.59 | 10,000 | 5,940 | 5,498,641 | Form | |
| 13 | Bp4, S.r.l. | Direct | Sell | 7222025 | 0.64 | 10,000 | 6,400 | 5,951,183 | Form | |
| 14 | Bp4, S.r.l. | Direct | Sell | 7102025 | 0.69 | 11,489 | 7,933 | 6,427,726 | Form | |
| 15 | Bp4, S.r.l. | Direct | Sell | 7102025 | 0.68 | 30,558 | 20,804 | 6,345,252 | Form | |
| 16 | Bp4, S.r.l. | Direct | Sell | 7102025 | 0.67 | 50,853 | 34,061 | 6,263,197 | Form | |
| 17 | Bp4, S.r.l. | Direct | Sell | 7022025 | 0.65 | 649 | 422 | 6,121,445 | Form | |
| 18 | Bp4, S.r.l. | Direct | Sell | 7022025 | 0.73 | 10,000 | 7,300 | 6,875,328 | Form | |
| 19 | Bp4, S.r.l. | Direct | Sell | 7022025 | 0.77 | 1,300 | 1,001 | 7,267,458 | Form | |
| 20 | Bp4, S.r.l. | Direct | Sell | 7022025 | 0.81 | 10,000 | 8,054 | 7,594,581 | Form | |
| 21 | Bp4, S.r.l. | Direct | Sell | 7022025 | 0.86 | 5,933 | 5,105 | 8,121,795 | Form | |
| 22 | Bp4, S.r.l. | Direct | Sell | 6202025 | 0.88 | 1,693 | 1,490 | 8,312,031 | Form | |
| 23 | Bp4, S.r.l. | Direct | Sell | 6202025 | 0.90 | 10,056 | 9,001 | 8,456,174 | Form | |
| 24 | Bp4, S.r.l. | Direct | Sell | 6132025 | 0.90 | 23,797 | 21,465 | 8,530,430 | Form | |
| 25 | Bp4, S.r.l. | Direct | Sell | 6112025 | 0.91 | 30,100 | 27,373 | 8,622,054 | Form | |
| 26 | Bp4, S.r.l. | Direct | Sell | 6112025 | 0.91 | 20,266 | 18,341 | 8,607,578 | Form | |
| 27 | Bp4, S.r.l. | Direct | Sell | 6102025 | 0.90 | 60,200 | 54,264 | 8,591,606 | Form | |
| 28 | Bp4, S.r.l. | Direct | Sell | 6102025 | 0.91 | 26,855 | 24,449 | 8,732,194 | Form | |
| 29 | Bp4, S.r.l. | Direct | Sell | 6062025 | 0.91 | 6,000 | 5,468 | 8,765,300 | Form | |
| 30 | Bp4, S.r.l. | Direct | Sell | 6062025 | 0.94 | 8,000 | 7,495 | 9,017,154 | Form | |
| 31 | Bp4, S.r.l. | Direct | Sell | 6032025 | 0.95 | 10,000 | 9,466 | 9,118,084 | Form | |
| 32 | Bp4, S.r.l. | Direct | Sell | 6032025 | 0.93 | 12,118 | 11,278 | 8,974,235 | Form | |
| 33 | Bp4, S.r.l. | Direct | Sell | 5302025 | 0.96 | 3,361 | 3,227 | 9,268,638 | Form | |
| 34 | Bp4, S.r.l. | Direct | Sell | 5302025 | 0.96 | 14,256 | 13,686 | 9,271,864 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.